Microorganism / grain / herb fermentation compound capable of delaying aging and aiding in sleep by cerebral dopamine production, method for preparing same, and use thereof

Abstract

Provided are a microorganism / grain / herb fermentation compound with the effects of delaying aging and aiding in sleep, a method for preparing same, and use thereof. The compound is prepared from Gastrodia elata rhizoma, black rice, and wheatgrass by means of fermentation, and can promote dopamine production, help maintain neural stability in brains, delay brain aging, protect brain nerves, and calm the nerves to help sleep.

Description

A fermented compound of Spartina officinalis that can delay aging and promote sleep through brain dopamine production, as well as its preparation method and application Technical Field

[0001] The present invention provides a Spartina officinalis fermentation compound that can delay aging and promote sleep through brain dopamine production. It can effectively promote the body's own production of dopamine, glutamate, and vitamin B6, thereby delaying brain aging, protecting brain nerves, and calming nerves to help induce sleep. Background Art

[0002] Dopamine is a key neurotransmitter that influences mood. It is an organic compound that plays several important roles in the brain and body, primarily synthesized in the human brain and kidneys. In the brain, dopamine acts as a neurotransmitter, sending signals to other nerve cells through the release of chemicals by neurons. Several major neurological diseases are associated with dysfunction of the dopamine system, leading to the use of key drugs that alter dopamine's effects. For example, Parkinson's disease, a degenerative condition that causes tremors and movement disorders, is caused by insufficient dopamine secretion by neurons in a region of the midbrain called the substantia nigra. Its precursor, L-dopa (L-DOPA), can be manufactured industrially, with levodopa being the most widely used treatment. Evidence suggests that schizophrenia involves altered dopamine activity levels, and most commonly used antipsychotic drugs primarily reduce dopamine activity. Restless legs syndrome and attention deficit hyperactivity disorder are also associated with decreased dopamine activity. Dopamine itself can be made into an intravenous drug. Although it cannot reach the brain from the blood, its peripheral effects make it useful for treating heart failure or shock, especially for newborns. In addition, studies have found that moderate dopamine can help sleep quality.

[0003] Glutamic acid (GA) is an amino acid found naturally in proteins. Because glutamic acid can be synthesized in the human body, it is classified as a non-essential amino acid. Glutamine is commonly found in animals and plants in various forms. It is also the most abundant excitatory neurotransmitter in the vertebrate nervous system and a precursor of gamma-aminobutyric acid (GABA).

[0004] Vitamin B6 (Vitamin B), also known as the anti-dermatitis vitamin or pyridoxine, is an essential B vitamin. Composed of six interconvertible vitamin isomers, it plays a crucial role in amino acid metabolism, serving as a coenzyme for enzymes such as amino acid decarboxylases and transaminases. The most common chemical form is pyridoxine; the most biologically active is pyridoxal phosphate, which acts as a coenzyme in over 140 enzyme reactions involved in amino acid, glucose, and lipid metabolism. Plants synthesize pyridoxine to protect against UVB rays and to synthesize chlorophyll. However, animals cannot synthesize vitamin B6 and therefore must obtain it through consumption of plants or other animals. While intestinal bacteria produce some vitamin B6, it is insufficient to meet animal needs. For adults, the recommended dietary allowance for vitamin B6 is 1.0 to 2.0 mg per day, with a safe upper limit of 25 to 100 mg per day. Vitamin B6 deficiency is rare, but common symptoms include rashes and inflammation of the mouth and eyes, lethargy, and peripheral neuropathy affecting the sensory and motor nerves in the hands and feet. Other symptoms include dermatitis, seizures, and anemia. Rare genetic disorders can also cause epileptic seizures in infants with vitamin B6 deficiency.

[0005] Gastrodia elata is a perennial, saprophytic, upright herb with a tuberous underground rhizome. It is a precious medicinal herb and is mentioned in numerous Chinese pharmacopoeias. For example, the Compendium of Materia Medica states, "Gastrodia elata is a medicine for the liver meridian and qi." Medicinal Gastrodia elata is the dried tuber of the plant, which is oblong or long, wrinkled, and has a distinct aroma, with a sweet and slightly pungent flavor. It is primarily found in Sichuan and Yunnan. Gastrodia elata is sweet, pungent, neutral, and non-toxic in nature. It enters the liver meridian and can calm wind and spasms, calm liver yang, and dispel wind and unclog the meridians. It is effective in treating convulsions, cramps, vertigo, headaches, hemiplegia, limb numbness, and rheumatic pain. It can be taken orally in a decoction of 3-10 grams, or it can be made into pills, powders, or ground into a powder for oral administration, with a dosage of 1-1.5 grams per dose. However, caution is advised for those with severe qi and blood deficiency.

[0006] Purple rice, also known as black rice, is a type of rice with a purplish-black color. Purple rice seeds can hybridize with other rice species, resulting in no reproductive isolation from other rice species, and they all belong to the rice family. Furthermore, black rice was also known as "forbidden rice" in ancient China, as it was generally only affordable for the upper class. The activity of hydrophilic antioxidants in purple rice bran is far greater than that of the lipophilic antioxidants anthocyanins and gamma-stanols, which are primarily located within the bran. Its lipophilic antioxidant extract, containing gamma-oryzanol, exhibits anti-inflammatory activity.

[0007] Wheatgrass (Catgrass) is a species of the genus Agropyron, specifically the young shoots of Agropyron cristatum (a relative of wheat). Its young leaves can be juiced or dried and ground into powder. While the raw plant contains a high amount of fiber, making it difficult for humans to digest, it also contains beneficial ingredients such as chlorophyll, amino acids, vitamins, minerals, and enzymes. Furthermore, the Compendium of Materia Medica describes the therapeutic benefits of wheatgrass: "Wheatgrass has a pungent, cold, and non-toxic aroma. It is primarily used to eliminate alcohol poisoning, sudden fever, alcohol sores, and jaundice... Mash and squeeze the juice, drinkable daily, to quench thirst, reduce chest heat, and benefit the small intestine..." This suggests that wheatgrass has anti-inflammatory and fever-reducing properties, as well as stomachic and digestive benefits and digestive benefits.

[0008] In the past, Gastrodia elata was mainly used as an additive in the form of Gastrodia elata extract. However, no research has confirmed that Gastrodia elata alone can actually stimulate the body's own production of dopamine or help the brain maintain neural stability. Therefore, additional ingredients such as phosphatidylserine and vitamins are also added to increase the effect of stabilizing brain nerves.

[0009] In view of this, the relevant field urgently needs to develop a Gastrodia elata fermentation complex that can truly promote dopamine and help the brain maintain neural stability, and to confirm through experiments its effects in delaying brain aging, protecting brain nerves, and calming nerves to help fall asleep.

[0010] Summary of the Invention

[0011] To address the problem that the aforementioned natural plant extracts are ineffective in helping the brain maintain neural stability, the present invention utilizes naturally derived ingredients, mixed in specific proportions, and fermented with probiotics to increase dopamine levels and the concentrations of the antioxidants SOD, GPx, and G6PD in brain tissue, while reducing the levels of the peroxides 8-oxodG and MDA in brain tissue, potentially delaying brain aging and protecting brain nerves.

[0012] In one embodiment of the present invention, a method for preparing a Japonica serrata fermentation complex that can delay aging and promote sleep through brain dopamine production comprises: a Japonica serrata raw material fragmentation stage, a negative pressure cell wall breaking stage, an extraction fermentation stage, and a modification fermentation stage.

[0013] The subsidiary technical means derived from the above necessary technical means are as follows: in the crushing stage of the juniper grass raw materials, multiple juniper grass raw materials are squeezed separately to obtain multiple juniper grass crude extracts.

[0014] Preferably, the raw materials of the rice grass are Gastrodia elata fruiting bodies, black rice and wheat grass.

[0015] Preferably, the plurality of crude extracts of Gastrodia elata fruiting bodies are crude extracts, Gastrodia elata fruiting body residues, crude black rice extracts, black rice residues, crude wheat grass extracts, and wheat grass residues.

[0016] The auxiliary technical means derived from the above necessary technical means are as follows: the negative pressure wall breaking stage is to place the crude extract of multiple fungi Spartina officinalis in the effect The first extract was obtained on the day of

[0017] The auxiliary technical means derived from the above necessary technical means are as follows: in the refined fermentation stage, 0.1-0.5% (w / w) of pectinase and the first extract are implanted with 0.2-2% (w / w) of lactic acid bacteria; in the refined fermentation stage, the fermentation temperature is controlled at The fermentation is continued for 8 to 14 days to obtain the first fermentation liquid.

[0018] The subsidiary technical means derived from the above necessary technical means are: in the modified fermentation stage: 0.2-2% (w / w) yeast or acetic acid bacteria is implanted into the first fermentation liquid; wherein the modified fermentation stage is to control the fermentation temperature at Continuous fermentation The second fermentation liquid obtained on the day.

[0019] In one embodiment of the present invention, the Spartina odorata fermentation complex comprises a plurality of Spartina odorata crude extracts, lactic acid bacteria, and yeast or acetic acid bacteria.

[0020] Preferably, the plurality of crude extracts of Gastrodia elata fruiting bodies are crude extracts, Gastrodia elata fruiting body residues, crude black rice extracts, black rice residues, crude wheat grass extracts, and wheat grass residues.

[0021] In one embodiment of the present invention, the Spartina officinalis fermentation complex increases the number and activity of lactic acid bacteria that synthesize gamma-aminobutyric acid (GABA) in the intestines of mammals.

[0022] In one embodiment of the present invention, the Spartina officinalis fermentation complex improves the sleep quality of an individual and can maintain the average deep sleep time of the individual within a normal range.

[0023] Preferably, the fermentation complex of Junmi grass can restore the oculomotor period to

[0024] In one embodiment of the present invention, the Spartina officinalis fermentation complex has the efficacy of preventing and / or treating Parkinson's disease.

[0025] In one embodiment of the present invention, the Spartina officinalis fermentation complex has the effect of enhancing the anti-oxidation effect of the brain.

[0026] In one embodiment of the present invention, the Spartina officinalis fermentation complex has a neuroprotective effect.

[0027] In one embodiment of the present invention, the Spartina officinalis fermentation complex has the efficacy of treating nerve damage.

[0028] In one embodiment of the present invention, the Spartina officinalis fermentation complex has the effect of preventing the decrease of dopamine in the brain.

[0029] In one embodiment of the present invention, the Spartina officinalis fermentation complex has the efficacy of treating decreased dopamine in the brain. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] FIG1 shows the sugar content changes of different strains during the fermentation stage of the refined product of the present invention;

[0031] FIG2 shows the pH changes of different strains during the fermentation stage of the refined product of the present invention;

[0032] FIG3 shows the sugar content changes of different strains during the modified fermentation stage of the present invention;

[0033] FIG4 shows the pH changes of different strains during the modified fermentation stage of the present invention;

[0034] FIG5 shows the sleep-inducing effect of the Spartina officinalis fermentation complex of the present invention, which can delay aging and promote sleep through brain dopamine production;

[0035] FIG6 shows the effect of the Spartina officinalis fermentation complex of the present invention on promoting dopamine content in the brain by delaying aging and promoting sleep through brain dopamine production;

[0036] FIG7 shows the effect of the Spartina officinalis fermentation complex of the present invention on tyrosine hydroxylase in brain tissue slices, which can delay aging and promote sleep through brain dopamine production;

[0037] FIG8 shows the effect of the Spartina officinalis fermentation complex of the present invention, which can delay aging and promote sleep through brain dopamine production, on the activity of the antioxidant enzyme G6PD in brain tissue;

[0038] FIG9 shows the effect of the Spartina officinalis fermentation complex of the present invention, which can delay aging and promote sleep through brain dopamine production, on the activity of the antioxidant GPx in brain tissue;

[0039] FIG10 shows the effect of the Spartina officinalis fermentation complex of the present invention, which can delay aging and promote sleep through brain dopamine production, on the activity of superoxide dismutase (SOD) in brain tissue;

[0040] FIG11 shows the effect of the Spartina officinalis fermentation complex of the present invention, which can delay aging and promote sleep through brain dopamine production, on the content of the oxide 8-oxodG in brain tissue;

[0041] FIG12 shows the effect of the Spartina officinalis fermentation complex of the present invention, which can delay aging and promote sleep through brain dopamine production, on the content of lipid peroxide MDA in brain tissue. DETAILED DESCRIPTION

[0042] The following describes the technical content of the present invention through specific embodiments. People skilled in the art can understand the advantages and effects of the present invention from the contents disclosed in this specification. However, the present invention can also be implemented or applied through other different specific embodiments.

[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which this invention pertains. Those skilled in the art will recognize many methods and materials similar or equivalent to those described herein that can be used to practice the present invention. Of course, the present invention is in no way limited to the methods and materials described.

[0044] The above embodiments are merely illustrative of the principles and effects of the present invention. Their purpose is to enable those skilled in the art to understand and implement the present invention accordingly. They are not intended to limit the present invention. Therefore, those skilled in the art may make equivalent modifications, alterations, and variations to the above embodiments without departing from the spirit of the present invention. The scope of the present invention shall be as set forth in the claims of the aforementioned patent application.

[0045] Example 1: Preparation of a Spartina officinalis fermentation complex

[0046] Gastrodia elata, black rice, and wheat sprouts are combined with lactic acid bacteria, yeast, or acetic acid bacteria to perform staged fermentation steps, and the fermented liquid is filtered and retained. The staged fermentation steps include:

[0047] (1) Crushing of the raw materials of Junmi grass: Wheat seedlings are squeezed physically until they are crushed, while retaining juice, pomace or leaf residue; Gastrodia elata and black rice are soaked in 70-100° C. hot water for 30 minutes to soften, and then squeezed until the fruiting bodies are in pieces, while retaining juice and residue;

[0048] (2) Negative pressure cell wall breaking stage: organic brown sugar, isomalto-oligosaccharide, sorbitol, granulated sugar, sucrose or a combination thereof is added at 0.2-1% (w / w) to increase the osmotic pressure of the extract. The extraction is then carried out under negative pressure in a near-vacuum environment of 20-60 cmHg for 5-14 days to break the cell walls of the fruits and vegetables and release the intracellular nutrients and polysaccharides.

[0049] (3) Extraction and fermentation stage: one or a combination of lactic acid bacteria (Lactobacillus plantarum, Lactobacillus delbrueckii, Lactococcus lactis, Lactobacillus acidophilus or B. bifidum) is implanted into the extract at a ratio of 0.2-2% (w / w). The fermentation temperature is controlled at 22-28°C and the fermentation is continued for 8-14 days. During this stage, the decomposition characteristics of lactic acid bacteria are utilized to produce a variety of decomposition enzymes to degrade the nutrients in fruits and vegetables into small molecules. During the fermentation process, 0.1-0.5% (w / w) pectin decomposition enzyme is added to increase the decomposition rate.

[0050] (4) Modification fermentation stage: one or a combination of yeast or acetic acid bacteria (Aspergillus fibuligera, Saccharomyces cerevisiae, Pichia faciens, S. pombe, A. hansenii, A. xylinum, A. suboxydans) is implanted into the extract at a ratio of 0.2-2% (w / w), the fermentation temperature is controlled at 22-28°C, and the fermentation is continued for 10-21 days. During this stage, the decomposition characteristics of microorganisms are utilized to produce a variety of decomposition enzymes to decompose the polysaccharide components into small molecules, the viscosity of the fermentation liquid is reduced and the fluidity is improved. After the fermentation is completed, the Spartina fermentation complex is obtained for use in the subsequent experiments of the embodiment.

[0051] Example 2: Comparison of stage fermentation tests

[0052] To test the effects of strains at different fermentation stages on fermentation performance and optimize fermentation results, the present invention further utilizes different strains for fermentation experiments. In the examples, two different strains were used in each of the two stages (Lactobacillus plantarum (LP) and Lactobacillus delbrueckii (LD) in the extract fermentation stage; and Aspergillus fibuligera (SF) and Saccharomyces cerevisiae (SC) in the modified fermentation stage) to compare fermentations and evaluate the optimal fermentation strain. During fermentation, the magnitude of changes in sugar content and pH are directly proportional to the fermentation activity of the strain. In short-term fermentations, the activity of the strain can significantly accelerate the completeness of fermentation. The results, shown in Tables 1 and 2 and Figures 1-4, demonstrate that different strains significantly impact fermentation performance. In the refined fermentation stage, Lactobacillus plantarum enhanced decomposition more effectively than Lactobacillus delbrueckii, while S. fibuligera reduced fermentation broth viscosity and improved fluidity compared to S. cerevisiae during the modified fermentation stage.

[0053] Example 3: Establishment of Parkinson's disease animal model

[0054] Establishment of Parkinson's model: The mice were divided into 4 groups: male mice, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced control group (Ctrl), MPTP-induced and administered with a low dose of Spartina ulmoides fermentation complex (L), MPTP-induced and administered with the recommended dose of Spartina ulmoides fermentation complex (M), and MPTP-induced and administered with a high dose of Spartina ulmoides fermentation complex (H); and 1 group of female mice, MPTP-induced and administered with a high dose of Spartina ulmoides fermentation complex (F), with 12 mice in each group. The groups that received the Spartina ulmoides fermentation complex were all given the complex by tube feeding for 28 consecutive days. The low-dose Spartina ulmoides fermentation complex tube feeding dose was 0.195 mg per gram of mouse body weight, equivalent to 250 mg / 70 kg / day for humans; the recommended dose of Spartina ulmoides fermentation complex tube feeding dose was 0.39 mg per gram of mouse body weight, equivalent to 500 mg / 70 kg / day for humans; and the high-dose Spartina ulmoides fermentation complex tube feeding dose was 1.17 mg per gram of mouse body weight, equivalent to 750 mg / 70 kg / day for humans.

[0055] Example 4: Experiment on the self-production of GABA in the intestine

[0056] The intestinal environment (pH 8.3) was simulated in a NaOH solution, and intestinal probiotics were added to simulate the intestinal bacteria and environment. 750 mg of the Spartina serrata fermentation complex was added to a 50 ml NaOH aqueous solution, and the solution was taken out every hour to detect bacterial counts and GABA content. In order to compare the differences between the Spartina serrata fermentation complex of the present invention and a conventional Gastrodia elata extract, a Spartina serrata extract complex formed by mixing Gastrodia elata, black rice, and wheat sprout extracts in the same ratio of the Spartina serrata fermentation complex was tested. The results are shown in Tables 3 and 4 below.

[0057] Table 3. Experimental results of the intestinal simulating GABA self-production experiment of the Spartina spp. fermentation complex

[0058] Table 4. Results of the experiment on the simulated GABA self-production in the intestine of the general Spartina extract complex

[0059] Comparison table three, table four can be seen, the bacterium rice grass fermentation complex of the present invention is under the environment of simulated intestinal flora, and intestinal tract releases GABA precursor (fermentation type), can be through the intestinal probiotic effect, promotes self-generation GABA; When slowly releasing up to more than 3 hours in intestinal tract, GABA is synthesized in a large amount in the 4th hour, for human body enters deep sleep optimal time, has stage property pressure relief, sleep-inducing effect. GABA precursor will slowly generate after entering blood-brain barrier, and generation time continues more than 8 hours, to ensure that GABA is completely absorbed and utilized by brain. However, general bacterium rice grass extract complex then is that GABA content reaches the highest peak because being absorbed by human body in 0.5 hour of taking, even surpasses bacterium rice grass fermentation complex of the present invention, but increase over time, GABA content declines gradually, representative bacterium rice grass extract complex cannot effectively promote self-generation GABA in human intestinal tract, on the contrary because absorption causes GABA content to increase over time and gradually reduce until exhausted, therefore bacterium rice grass fermentation complex of the present invention and unfermented general bacterium rice grass extract complex have great difference in essence.

[0060] Example 5: Human sleep monitoring

[0061] Eighteen men and women aged 20 to 60 were given 750 mg of a fermented complex from Spartina officinalis 30 minutes before bedtime and monitored their sleep over a five-day period while wearing smart wearable devices. The researchers monitored sleep duration and the duration of REM sleep. The study indicates that a 5% decrease in REM sleep is associated with a 17% increased mortality rate and a higher risk of dementia.

[0062] The results, as shown in Figure 5, show that deep sleep time increased for all participants on the first day of use, with an average increase of 4.6% in deep sleep and a 5.09% reduction in REM sleep. On the second day, deep sleep time decreased slightly, while REM sleep increased significantly, indicating that body functions gradually recovered and brain function began to strengthen, consolidating memory. After the third day, average deep sleep time remained within the normal range, with REM sleep accounting for 20-25%, well within the healthy range.

[0063] Example 6: Determination of dopamine concentration in the brain

[0064] Dopamine is mainly found in the human brain area, commonly known as the happy hormone, which controls mood and stress changes. Moderate dopamine secretion helps sleep.

[0065] The experiment used drugs to induce Parkinson's disease in young mice. Male mice were tube-fed three different doses, and female mice were tube-fed the highest dose. The mice were continuously given the Spartina fermentation complex for 28 days before being sacrificed. After sacrifice, the striatum of the mice was removed to measure the dopamine concentration in the mouse brain and analyze the dopamine concentration in their brain tissue.

[0066] The results, as shown in Figure 6, showed significant differences between the mice with substantia nigra injury treated with the low and recommended doses, indicating that the low and recommended doses have significant therapeutic effects, but there are still significant differences compared to healthy mice. Therefore, the evaluation is based on the use of a dose that can be used for preventive effects. Male and female mice with substantia nigra injury treated with the high dose showed no significant differences compared to healthy mice, indicating that the high dose has a therapeutic effect on dopamine deficiency. Therefore, in summary, the low and recommended doses have a preventive effect on dopamine deficiency, while the high dose can be used as an effective dose for treatment.

[0067] Example 7: Testing for the Level of Tyrosine Hydroxylase, a Precursor of Dopamine in the Brain

[0068] Tyrosine hydroxylase (TH) in brain tissue is considered to be the basis of dopamine secretion. A decrease in TH concentration leads to a decrease in dopamine production, which can lead to sleep disorders, depression, and inattention.

[0069] The experiment used drugs to induce Parkinson's disease in young mice. Male mice were tube-fed three different doses, and female mice were tube-fed the highest dose. The drug was continuously administered for 28 days to the mice, after which the mice were sacrificed. Brain tissue was removed and dehydrated, embedded, sectioned, and stained. TH immunostaining was performed, and pathological changes in the dopamine precursor tyrosine hydroxylase (TH) in the brain tissue were observed under an optical microscope. TH levels were used as a basis for diagnosis and evaluation.

[0070] The results, as shown in Figure 7, showed a difference in mice with substantia nigra injury treated with a low dose, indicating that the low dose has a normal health-promoting effect and can be used as a preventive measure. Mice with substantia nigra injury treated with the recommended dose showed a significant difference, and the therapeutic effect was significantly higher than that of the low-dose group, but there was still a significant difference compared to healthy mice. Male and female mice with substantia nigra injury treated with a high dose showed no significant difference from healthy mice, indicating that the high dose has the effect of preventing dopamine deficiency. Therefore, in summary, the low dose and the recommended dose have the effect of preventing substantia nigra injury, and the high dose can be used as an effective therapeutic dose.

[0071] Example 8 Antioxidant Index Content in Blood

[0072] The aging of dopamine neurons is generally believed to be due to oxidative atrophy caused by excessive oxidation. Therefore, a higher antioxidant index indicates a stronger ability to protect nerve cells. The presence of the G6PD enzyme in brain tissue can produce antioxidants to combat free radical damage. Studies have shown that low G6PD activity in patients can lead to a loss of antioxidant capacity. SOD is a comprehensive free radical antioxidant enzyme, and its activity can be used to assess the strength of an organism's antioxidant capacity, making it a commonly used antioxidant indicator.

[0073] The experiment used drug-induced aging Parkinson's disease model mice, feeding them three different doses for 12 weeks. Blood samples were taken from the mice to analyze the activity of the antioxidant indicators SOD, G6PD and GPx.

[0074] The results are shown in Figures 8-10. Whether it is the content of antioxidant indicators such as G6PD, GPx, or SOD, there are significant differences in the content of substantia nigra injury mice after low-dose treatment, indicating that the low dose has a significant therapeutic effect, but there are still significant differences compared with healthy mice. There are significant differences in the content of substantia nigra injury mice after treatment with the recommended dose, and the therapeutic effect is significantly higher than that of the low-dose group, but there are still significant differences compared with healthy mice. There is no significant difference between male and female substantia nigra injury mice and healthy mice after high-dose treatment, indicating that the high dose has the effect of preventing dopamine secretion deficiency. Therefore, in summary, low doses and recommended doses have the effect of preventing dopamine deficiency and protecting neurons, and high doses can be used as effective therapeutic doses.

[0075] Example 9: Determination of brain tissue oxide concentration

[0076] Studies have shown that 8-oxodG is a strong free radical oxidant, which can cause neuronal damage in the brain.

[0077] The experiment used drug-induced aging Parkinson's disease model mice. Male mice were fed three different doses and female mice were fed the highest dose. After 28 days of continuous administration of the Spartina fermentation complex, the mice were sacrificed, their brain tissue was removed, and the mitochondria in the brain tissue were isolated. Mitochondrial DNA was then extracted and analyzed for the content of 8-oxodg in the brain mitochondrial DNA to assess the degree of mitochondrial DNA damage.

[0078] The results are shown in Figure 11. After the mice with substantia nigra injury were treated with a low dose, there was a significant difference, indicating that the low dose had a significant therapeutic effect, but there was still a significant difference from the healthy mice. After the mice with substantia nigra injury were treated with the recommended dose, there was a significant difference, and the therapeutic effect was significantly higher than the low-dose group, but there was still a significant difference from the healthy mice. After the male and female mice with substantia nigra injury were treated with a high dose, there was no significant difference from the healthy mice, indicating that the high dose had a neuronal protective effect. Therefore, in summary, the low dose and the recommended dose have the effect of preventing neuronal damage, and the high dose can be used as an effective dose for treating neuronal damage.

[0079] Example 10: Determination of Lipid Oxide Concentration in Brain Tissue

[0080] Malondialdehyde (MDA) is a lipid peroxide that can cause neuronal damage when present in the brain.

[0081] The experiment used drug-induced aging in Parkinson's disease mice. Male mice were gavage-fed three different doses of the fermentation complex of Spartina officinalis, and female mice were gavage-fed the highest dose. The mice were then sacrificed for 28 days, and brain tissue samples were removed for analysis of the MDA content. Reactive oxygen species (ROS) cause lipid peroxidation to form MDA, which affects oxidative reactions in cell membranes, lipoproteins, and other lipid-containing molecules, leading to oxidative neuronal atrophy.

[0082] The results are shown in Figure 12. After the mice with substantia nigra injury were treated with a low dose, there was a significant difference, indicating that the low dose had a significant therapeutic effect, but there was still a significant difference compared with healthy mice. After the mice with substantia nigra injury were treated with the recommended dose, there was a significant difference, and the therapeutic effect was significantly higher than that of the low-dose group, but there was still a significant difference compared with healthy mice. After high-dose treatment, male and female mice with substantia nigra injury showed no significant difference from healthy mice, indicating that the high dose has a neuronal protective effect. Therefore, in summary, the low dose and the recommended dose have the effect of protecting neurons, and the high dose can be used as an effective dose for treating damaged neurons.

[0083] The above experimental data are preliminary experimental results obtained under specific conditions and are only used to facilitate understanding or reference of the technical content of the present invention. Other related experiments are still needed. The experimental data and its results are not intended to limit the scope of the present invention.

[0084] The aforementioned preferred embodiments are merely examples of the present invention and its technical features. The technology of this embodiment may still be appropriately implemented in various substantially equivalent modifications and / or replacement methods; therefore, the scope of rights of the present invention shall be subject to the scope defined in the claims of the patent application.

Claims

1. A preparation method of a fermented complex of Junmicao with the functions of delaying aging and promoting sleep through the production of brain dopamine, characterized in that, It includes the following steps: Fragmentation stage of Juncao raw materials: The Juncao raw materials are respectively obtained through pressing to obtain Juncao crude extracts, where the Juncao raw materials are Gastrodia elata fruit bodies, black rice, and wheatgrass; the Juncao crude extracts are Gastrodia elata fruit body crude extracts, Gastrodia elata fruit body residues, black rice crude extracts, black rice residues, wheatgrass crude extracts, and wheatgrass residues; Negative pressure cell wall breaking stage: subjecting the complex Spartina extract to Under, the effect for [X] days to obtain the first extract; Essence fermentation stage: implant 0.1-0.5% (w / w) of pectin-decomposing enzyme and the first extract into 0.2-2% (w / w) of lactic acid bacteria, wherein the essence fermentation stage controls the fermentation temperature at Ferment continuously for 8 - 14 days to obtain the first fermentation broth; Modification fermentation stage: implant 0.2-2% (w / w) of yeast or acetic acid bacteria into the first fermentation broth, and control the fermentation temperature of the modification fermentation stage at Continuous fermentation for [X] days to obtain the second fermentation broth.

2. The preparation method according to claim 1, characterized in that, The fragmentation stage of the Juncao raw material further includes a hot water treatment step, in which the Gastrodia elata fruit body, black rice and wheat grass are soaked in hot water for 30 minutes.

3. The preparation method according to claim 1, characterized in that, The negative pressure cell wall breaking stage further includes a step of increasing the osmotic pressure, and the step of increasing the osmotic pressure is to add saccharides to the crude extract of the complex Spartina alterniflora Loisel.

4. The preparation method according to claim 3, characterized in that, The saccharides include one or more of organic brown sugar, isomaltooligosaccharide, sorbitol, granulated sugar, and sucrose.

5. The preparation method according to claim 1, characterized in that, The lactic acid bacteria include one or more of Lactobacillus plantarum, Lactobacillus delbrueckii, Lactococcus lactis, Lactobacillus acidophilus, or Bifidobacterium bifidum.

6. The preparation method according to claim 1, characterized in that, The yeast or the acetic acid bacteria include one or more of Saccharomycopsis fibuligera, Saccharomyces cerevisiae, Pichia faciens, Schizosaccharomyces pombe, Acetobacter hansenii, Acetobacter xylinum, or Acetobacter suboxydans.

7. The preparation method according to claim 1, characterized in that, It also includes a granulation stage, where the second fermentation broth is filtered and granulated by spray drying.

8. A fermented complex of Juncao and rice that can delay aging and promote sleep through the generation of brain dopamine, obtained according to the preparation method described in claim 1, characterized in that, The Juncao fermentation complex includes the plural Juncao crude extracts, the lactic acid bacteria, and the yeast or the acetic acid bacteria, where the plural Juncao crude extracts are Gastrodia elata fruit body crude extracts, Gastrodia elata fruit body residues, black rice crude extracts, black rice residues, wheatgrass crude extracts, and wheatgrass residues.

9. Use of a fermented complex of Juncus effusus L. obtained by the preparation method according to claim 1, characterized in that, The Juncao fermentation complex increases the number and activity of lactic acid bacteria that can synthesize γ-aminobutyric acid in the mammalian intestine.

10. The use according to claim 9, characterized in that, It can effectively increase a γ-aminobutyric acid (GABA) precursor in the mammalian intestine.

11. The use according to claim 9, characterized in that, The continuous generation time of the γ-aminobutyric acid (GABA) precursor lasts for more than 8 hours.

12. The use according to claim 9, characterized in that, The mammals are selected from cats, dogs, rabbits, cows, horses, sheep, goats, monkeys, mice, rats, gerbils, guinea pigs, pigs, or humans.

13. Use of a fermented complex of Juncus effusus L. obtained by the preparation method as described in claim 1 for the preparation of a medicament for improving the sleep quality of an individual, characterized in that, The average deep sleep time of the individual can be maintained within the normal range, and the proportion of the rapid eye movement (REM) period can be restored and maintained at The effective dose of the fermented complex of Spartina anglica is 250 mg / 70 kg person / day to 750 mg / 70 kg person / day per dose.

14. Use of the fermented complex of Juncus effusus obtained by the preparation method as described in claim 1 for the preparation of a medicament for preventing Parkinson's disease, characterized in that, The effective dose of the Juncao fermentation complex is 250 mg / 70 kg human / day to 750 mg / 70 kg human / day per dose.

15. Use of a fermented complex of Juncus effusus prepared by the preparation method as described in claim 1 for the preparation of a medicament for treating Parkinson's disease, characterized in that, The effective dose of the Juncao fermentation complex is 500 mg / 70 kg human / day to 750 mg / 70 kg human / day per dose.

16. Use of a Junmicao fermentation complex obtained by the preparation method as described in claim 11 for the preparation of a drug for enhancing brain antioxidant indexes, characterized in that, The antioxidant indexes are SOD activity, G6PD activity, and GPx activity, where the effective dose of the Juncao fermentation complex is 250 mg / 70 kg human / day to 750 mg / 70 kg human / day per dose.

17. Use of the fermented complex of Juncus effusus obtained by the preparation method as described in claim 1 for the preparation of a drug for protecting nerves, characterized in that, The effective dose of the Juncao fermentation complex is 250 mg / 70 kg human / day to 750 mg / 70 kg human / day per dose, where the nerve protection includes preventing neuron damage or preventing substantia nigra damage in the brain.

18. Use of a fermented complex of Juncus effusus L. obtained by the preparation method as described in claim 1 for the preparation of a medicament for treating nerve injury, characterized in that, The effective dose of the fermented complex of Spartina alterniflora Loisel is 500 mg / 70 kg human / day to 750 mg / 70 kg human / day per dose, wherein the treatment of nerves includes treating damaged neurons or treating substantia nigra damage.

19. Use of a fermented complex of Juncus effusus L. obtained by the preparation method as described in claim 1 for the preparation of a drug for preventing the reduction of dopamine in the brain, characterized in that, The effective dose of the fermented complex of Spartina alterniflora Loisel is 250 mg / 70 kg human / day to 750 mg / 70 kg human / day per dose.

20. Use of a fermented complex of Spartina alterniflora Loisel obtained by the preparation method as described in claim 1 for the preparation of a drug for treating reduced dopamine in the brain, wherein the effective dose of the fermented complex of Spartina alterniflora Loisel is 500 mg / 70 kg human / day to 750 mg / 70 kg human / day per dose.

Images